A pancreatic tumor whole cell vaccine based on proteasome inhibitor and preparation method thereof

By inducing immunogenic cell death with bortezomib, the immunogenicity of pancreatic tumor whole-cell vaccine is improved, and the problem of insufficient vaccine immunogenicity in the prior art is solved, and the effect of enhancing CD8+ T cell function and inhibiting pancreatic cancer growth is achieved.

CN119745899AInactive Publication Date: 2025-04-04THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
4 Cites 0 Cited by

Patent Information

Application Number
CN202510259542.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-03-06
Publication Date
2025-04-04
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve the immunogenicity of pancreatic tumor whole-cell vaccine, resulting in limited clinical application.

Method used

The proteasome inhibitor bortezomib was used to induce immunogenic cell death, which enhances the immunogenicity of the vaccine by promoting mRNA expression of related molecules, phosphorylation of PERK and eIF2a, release of HMGB1 and ATP, and the display of the endoplasmic reticulum of calreticulin to the cell membrane surface.

Benefits of technology

It significantly improved the immunogenicity of pancreatic tumor whole-cell vaccine, enhanced the infiltration and killing function of CD8+ T cells, and coordinated inhibited the growth of pancreatic cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a pancreatic tumor whole-cell vaccine based on a proteasome inhibitor and a preparation method thereof. The proteasome inhibitor can activate anti-pancreatic cancer immune effects in an immune-dependent manner, thereby inhibiting the growth of pancreatic cancer. At the same time, the expression of immunogenic damage-related molecule mRNA in cells can be promoted in vitro, and the phosphorylation levels of PERK and eIF2a in KPC cells can be increased to activate the body's immune effects. Treatment with the proteasome inhibitor bortezomib can induce immunogenic cell death of tumor cells. The prepared tumor whole-cell vaccine can enhance its immunogenicity to better activate the body's immune effects, thereby providing a new idea for the clinical transformation of tumor whole-cell vaccines.
Need to check novelty before this filing date? Find Prior Art